Noticias y vídeos - REGENXBIO INC.

REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD PR Newswire ROCKVILLE, Md., March 28, 2024 A single ABBV-RGX-314 gene therapy treatment has the potential to become a new standard-of-care option among anti-VEGF treatments by sustaining vision health long term and overcoming the clinical challenges of managing wet AMD due to the treatment burden of chronic anti-VEGF injections Patients who received therapeutic doses...

REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days PR Newswire ROCKVILLE, Md., March 27, 2024 ROCKVILLE, Md. , March 27, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days on Wednesday, April 3, 2024 . Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days Fireside Chat: Wednesday, April 3, 2024 at 9:50 a.m. EDT Location: Virtual A live webcast of the fireside chat...

REGENXBIO to Participate in Upcoming Investor Conferences PR Newswire ROCKVILLE, Md., March 11, 2024 ROCKVILLE, Md. , March 11, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate the following upcoming investor conferences: Leerink Partners 2024 Global Biopharma Conference Date: Tuesday, March 12, 2024 Location: Miami, FL 1x1 investor meetings only Barclays 26th Annual Global Healthcare Conference Fireside Chat: Wednesday, March 13, 2024 at 4:05 p.m. ET Gene...

REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants PR Newswire ROCKVILLE, Md., March 6, 2024 ROCKVILLE, Md. , March 6, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy, today announced the pricing of an underwritten upsized public offering of 4,565,260 shares of its common stock at the price of $23.00 per share and 1,521,740...

REGENXBIO Announces Proposed Public Offering of Common Stock PR Newswire ROCKVILLE, Md., March 6, 2024 ROCKVILLE, Md. , March 6, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it intends to offer and sell, subject to market conditions, $125,000,000 of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of...

REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIAL PR Newswire ROCKVILLE, Md., March 5, 2024 New three-month assessment in first patient at dose level 2 demonstrates robust microdystrophin expression Patient aged 12 years at dosing had expression level at 75.7% of control Early evidence of strength and motor function improvement observed On track to initiate pivotal trial in second half of 2024 Webcast this morning, Tuesday, March 5 , 8:30 a.m. ET , with...

REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial PR Newswire ROCKVILLE, Md., Feb. 29, 2024 Company to host webcast on Tuesday, March 5, 2024 at 8:30 a.m. EST Interim clinical data will be presented by Aravindhan Veerapandiyan, M.D., primary investigator of the AFFINITY DUCHENNE trial, at the MDA Clinical & Scientific Conference on Wednesday, March 6, 2024 at 12:00 p.m. EST ROCKVILLE, Md. , Feb. 29, 2024 /PRNewswire/ -- REGENXBIO...

REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights PR Newswire ROCKVILLE, Md., Feb. 27, 2024 Focus on clinical stage AAV Therapeutic product candidates addressing large commercial opportunities and value generation Prioritized pipeline is expected to further progress to pivotal stage and first BLA filing in 2024 New updates planned for Duchenne and in-office delivery retinal disease programs starting in March $314 million in cash, cash...

REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights PR Newswire ROCKVILLE, Md., Feb. 21, 2024 ROCKVILLE, Md. , Feb. 21, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Tuesday, February 27, 2024 , at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full year ended December 31, 2023 , and recent operational highlights....

REGENXBIO Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint PR Newswire ROCKVILLE, Md., Feb. 7, 2024 Results support BLA submission in 2024 using the accelerated approval pathway Primary endpoint of patients achieving reduction in CSF biomarker of MPS II disease was met with statistical significance (p value of 0.00016) Patients treated with RGX-121 have showed continued improvement in neurodevelopmental skill acquisition up to four years and discontinued...

REGENXBIO Announces Presentations at the 20th Annual WORLDSymposium 2024 PR Newswire ROCKVILLE, Md., Jan. 31, 2024 Pivotal topline results from the CAMPSIITE ® trial of RGX-121 for the treatment of MPS II to be presented Conference call Wednesday, February 7, 4:30 p.m. ET ROCKVILLE, Md. , Jan. 31, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations on its program for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, will be...

REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery PR Newswire ROCKVILLE, Md., Jan. 16, 2024 A single ABBV-RGX-314 gene therapy treatment has the potential to become a new standard-of-care option among anti-VEGF treatments by sustaining vision health long term and overcoming the clinical challenges of managing wet AMD due to the treatment burden of chronic anti-VEGF injections ABBV-RGX-314 continues...

REGENXBIO Announces Presentation at the Hawaiian Eye and Retina 2024 Meeting PR Newswire ROCKVILLE, Md., Jan. 10, 2024 ROCKVILLE, Md. , Jan. 10, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present data from the Phase II AAVIATE ® trial of suprachoroidal ABBV-RGX-314 for the treatment of wet age-related macular degeneration (AMD) at Hawaiian Eye and Retina 2024 Meeting being held January 13-19, 2024 in Maui, HI . ABBV-RGX-314 is an investigational one-time AAV...

U.S. District Court Issues Decision on REGENXBIO and University of Pennsylvania NAV® Technology Patent Infringement Lawsuit PR Newswire ROCKVILLE, Md., Jan. 8, 2024 ROCKVILLE, Md. , Jan. 8, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the U.S. District Court for the District of Delaware granted Sarepta Therapeutics, Inc. (Sarepta) summary judgment on invalidity in a patent infringement suit arising from Sarepta's manufacture and use of cultured host cell technology covered...

REGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE® Trial PR Newswire ROCKVILLE, Md., Nov. 29, 2023 First patient received dose level 2 of RGX-202, a potential one-time AAV Therapeutic for the treatment of Duchenne that includes an optimized transgene for a novel microdystrophin On track for pivotal dose determination and initiation of pivotal program in 2024 ROCKVILLE, Md. , Nov. 29, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that the first patient received...

REGENXBIO Announces Updated Strategic Plans and Third Quarter 2023 Financial Results PR Newswire ROCKVILLE, Md., Nov. 8, 2023 Announces pipeline prioritization and corporate restructuring to focus on clinical stage AAV Therapeutic product candidates addressing large commercial opportunities and value generation Highest priority programs are ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne, and...

REGENXBIO to Participate in Upcoming Investor Conferences PR Newswire ROCKVILLE, Md., Nov. 7, 2023 ROCKVILLE, Md. , Nov. 7, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate the following upcoming investor conferences: Stifel 2023 Healthcare Conference Fireside Chat Date: Tuesday, November 14, 2023 Fireside Chat Time: 3:00 p.m. ET Location: New York, NY Piper Sandler 35 th Annual Healthcare Conference Fireside Chat Date: Wednesday, November 29, 2023 Fireside...

REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery PR Newswire ROCKVILLE, Md., Nov. 3, 2023 ABBV-RGX-314 continues to be well tolerated in 50 patients from dose levels 1 and 2 (Cohorts 1-3) with no drug-related serious adverse events Dose level 2 prevented disease progression and reduced vision-threatening events in non-proliferative diabetic retinopathy patients at 1 Year 70.8% of patients...

REGENXBIO to Host Conference Call on November 8 to Discuss Third Quarter 2023 Financial Results and Recent Operational Highlights PR Newswire ROCKVILLE, Md., Nov. 1, 2023 ROCKVILLE, Md. , Nov. 1, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, November 8, 2023 , at 4:30 p.m. EST to discuss its financial results for the quarter ended September 30, 2023 , and recent operational highlights. Listeners can register for the webcast...

REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting PR Newswire ROCKVILLE, Md., Oct. 30, 2023 ROCKVILLE, Md. , Oct. 30, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Academy of Ophthalmology (AAO) 2023 Annual Meeting being held November 3-6, 2023 in San Francisco, CA. The presentations will highlight new data for ABBV-RGX-314, an investigational one-time AAV Therapeutic being developed in collaboration...